Last reviewed 2026-04-23 · How we verify

ivermectin (IVM)

Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite.

Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite. Used for Onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.

At a glance

Mechanism of action

Ivermectin is an antiparasitic agent that selectively binds to invertebrate-specific glutamate-gated chloride ion channels, increasing chloride conductance and hyperpolarizing the cell membrane. This leads to paralysis and death of susceptible parasites including nematodes and arthropods. The drug has high selectivity for parasitic channels over mammalian GABA receptors, providing a favorable safety profile.

Approved indications

• Onchocerciasis (river blindness)
• Lymphatic filariasis
• Strongyloidiasis
• Scabies
• Lice infestations

Common side effects

• Pruritus
• Headache
• Dizziness
• Arthralgia/myalgia
• Fever
• Lymphadenopathy

Key clinical trials

• Moxidectin for LF, Cote d'Ivoire (DOLF) (PHASE3)
• Ivermectin Repurposed for the Treatment of PKDL (EARLY_PHASE1)
• Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
• Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms (PHASE2, PHASE3)
• Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness (PHASE3)
• Repeat Ivermectin Mass Drug Administrations for MALaria Control II (PHASE3)
• Co-administration of IVM and ALB in School-based Deworming in Uganda
• Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.